

Dopamine: Receptors, Functions, Synthesis, Pathways, Locations and Mental Disorders: Review of Literatures

Getinet Ayano*

Chief Psychiatry Professional and mhGap Coordinator at Research and Training Department, Amanuel Mental Specialized Hospital, Addis Ababa, PO box: 1971, Addis Ababa, Ethiopia

Abstract

Dopamine is monoamine neurotransmitter. Dopamine is produced in the dopaminergic neurons in the ventral tegmental area of the substantia nigra, midbrain and the arcuate nucleus of the hypothalamus. In the periphery, dopamine is found in the kidney where it functions to produce renal vasodilation, diuresis, and natriuresis. Dopamine neurons are more widely distributed than those of other monamines and it is found in hypothalamus, olfactory bulb, the midbrain substantia nigra and ventral tegmental area and in the periaqueductal gray and retina.

There are five subtypes of dopamine receptors, D₁, D₂, D₃, D₄, and D₅, which are members of the large G-protein coupled receptor super family. The dopamine receptor subtypes are divided into two major subclasses: types 1 and 5 are similar in structure and drug sensitivity, and these two receptors are referred to as the "D₁like" group or class of receptors. Dopamine receptor types 2, 3, and 4 are called the "D₂like" group. Dopamine plays central role in pleasurable reward behavior, inhibition of prolactin production (involved in lactation), sleep, mood, attention, learning, behavior, control of nausea and vomiting and pain processing. In addition it also involved in controlling movement, emotion and cognition.

Due to extensive localization of dopamine receptor to brain areas and its role in wide range of functions, dopaminergic dysfunction has been implicated in the pathophysiology of schizophrenia, mood disorders, obsessive compulsive disorder (OCD), autism spectrum disorders, attention deficit-hyperactivity disorder (ADHD), tourette's syndrome, substance dependency, Parkinson's disease and other disorders.

Keywords: Dopamine; Receptors; Synthesis; Locations; Mental disorders

Dopamine Receptors

There are five subtypes of dopamine receptors, D₁, D₂, D₃, D₄, and D₅, which are members of the large G-protein coupled receptor super family [1]. The dopamine receptor subtypes are divided into two major subclasses: types 1 and 5 are similar in structure and drug sensitivity, and these two receptors are referred to as the "D₁like" group or class of receptors. Dopamine receptor types 2, 3, and 4 are also similar in structure and are, therefore, grouped together as the "D₂like" group [2]. Dopamine receptors are typically couple to G_s and G_i mediated transduction systems [3].

The ultimate effect of D₁-like activation (D₁ and D₅) can be excitation (via opening of sodium channels) or inhibition (via opening of potassium channels); the ultimate effect of D₂-like activation (D₂, D₃, and D₄) is usually inhibition of the target neuron [2]. The effect of dopamine on a target neuron depends on which types of receptors are present on the membrane of that neuron and on the internal responses of that neuron to the second messenger cAMP [2]. D₁ receptors are the most numerous dopamine receptors in the human nervous system and D₂ receptors are the second most abundant receptors. D₃, D₄, and D₅ receptors are present at significantly lower levels [2].

D₁ and D₅ receptors mostly involved in post synaptic inhibition. D₂, D₃, and D₄ receptors are involved in both pre-and postsynaptic inhibition. D₂ receptors regulates mood, emotional stability in the limbic system and movement control in the basal ganglia [3,4].

D₁ and D₂ receptors were distinguished on the basis of differential binding affinities of a series of agonists and antagonists, distinct effectors mechanisms, and distinct distribution patterns within the CNS. It was subsequently found that the therapeutic efficacy of antipsychotic drugs correlated strongly with their affinities for

the D₂ receptor, implicating this subtype as an important site of antipsychotic drug action [3,4].

D₁ receptor has high affinity for the antagonist SCH 23390 and relatively low affinity for butyrophenones such as haloperidol. D₁ receptor activation stimulates cyclic adenosine monophosphate (cAMP) formation, D₂ receptor stimulation produces the opposite effect. In addition to the stimulation of adenylate cyclase, D₁ receptors may also stimulate phosphoinositide turnover and modulate intracellular calcium levels [1,3].

The D₁ receptors are found in high concentration in the hippocampus, caudate, putamen, nucleus accumbens, hypothalamus, substantia nigra pars reticulata, olfactory tubercle and frontal and temporal cortex [3,5]. D₁ receptors have been implicated in the cognitive functions of dopamine such as the control of working memory and attention. D₁ receptors contribute significantly to the CNS effects of cocaine, suggesting the involvement of other receptors in addition to the D₂ receptor, in mediating rewarding effects of drugs of abuse [1,3,5].

D₁ and D₅ receptors have a higher degree of homology with each other than with the D₂₋₄ subtypes. D₅ receptor has 50% homology

***Corresponding author:** Getinet Ayano, Chief Psychiatry Professional and mhGap Coordinator at Research and Training Department, Amanuel Mental Specialized Hospital, Addis Ababa, PO box: 1971, Addis Ababa, Ethiopia, Tel: +251-9-27-17-29-68; E-mail: ayanogetinet@yahoo.com

Received July 18, 2016; Accepted July 26, 2016; Published August 02, 2016

Citation: Ayano G (2016) Dopamine: Receptors, Functions, Synthesis, Pathways, Locations and Mental Disorders: Review of Literatures. J Ment Disord Treat 2: 120. doi:10.4172/2471-271X.1000120

Copyright: © 2016 Ayano G. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

with D1. This structural similarity is reflected in the similar affinities of a wide variety of dopaminergic drugs for these two receptors. The main distinguishing feature of their binding profiles is that the binding affinity of dopamine is higher for the D₅ receptor than that for the D₁ receptor. D5 receptor is expression in nucleus of thalamus suggesting that role in pain stimuli [1,3,6].

D2 receptor is highly expressed in basal ganglia, septum, ventral tegmental area and nucleus accumbens. D3 receptors mediate positive regulatory influences of dopamine on production of neurotension. D4 receptors homology with D2 and D3 41% and 39% respectively and they are found in hippocampus and frontal cerebral cortex [6-8].

Although the D1like receptors are mentioned as a primary target for antipsychotic drugs, several findings indicate that they are not clinically relevant. Of the 3 D2 like receptors, only the D2 receptor itself is blocked by antipsychotic drugs in direct relation to their clinical antipsychotic potencies [3].

The D1 receptors are linked to adenylate cyclase which, when activated, produces cyclic AMP as a secondary messenger. The D2 receptors are not positively linked to adenylate cyclase and may owe their physiological effects to their ability to inhibit this enzyme. The D2 receptors are probably the most important postsynaptic receptors mediating behavioural and extrapyramidal activity. Most therapeutically effective neuroleptics block the D2receptors, while drugs like bromocriptine, which is a dopamine receptor agonist used in the treatment of parkinsonism, activate them. The correlation between the antagonist effect of a series of neuroleptics on brain [3,4].

Agonist stimulation of D1 receptors results in cyclic adenosinemonophosphate (cyclic AMP) synthesis followed by phosphorylation of intracellular proteins, including dopamine- and AMP-regulated phosphoprotein (DARPP-32). The receptor binding affinity of a dopamine agonist independent on the degree of association of the receptor and the guanine nucleotide binding regulatory protein, which is regulated by guanosinetriphosphate (GTP) and calcium or magnesium ions. Thus the D1 receptor may exist in a high or low agonist affinity state depending on the balance between GTP (which favors low affinity) and the divalent cations (which favor high affinity). The high affinity D1 receptor is classified as a D5 receptor [4,6].

The D3 and D4 receptors appear to be largely restricted to the limbic areas of the rat and human brain. These receptors are of particular interest as they have a high affinity for such atypical neuroleptics as clozapine. Such findings suggest that the D3 and D4 receptors in the human brain may mediate the antipsychotic actions of many typical and atypical neuroleptics. The restriction of these receptors to the limbic regions may lead to the development of neuroleptics which are specifically targeted to these areas [6,7] (Table 1).

Dopamine System and Functions

There are four major pathways for the dopaminergic system in the brain:

The Nigro-Stiatal Pathway, In which fibres originate from the substantia nigra (pars compacta) and project rostrally to become widely distributed in the basal ganglia (caudate nucleus and the putamen). In this pathway dopamine plays a significant role in movement (the control of motor function and in learning new motor skills). Degeneration of the nigrostriatal system causes Parkinson's disease [9-11]. Dopamine cell bodies in the pars compacta division of this region send ascending projections to the dorsal striatum (especially to the caudate and putamen) and thereby modulate motor control. The extrapyramidal

effects of antipsychotic drugs are thought to result from the blockade of these striatal dopamine receptors [10,11].

The Mesolimbic Pathway, where the dopaminergic projections originate in the ventral tegmental area, and then spread to the amygdala, pyriform cortex, lateral septal nuclei and the nucleus accumbens. In this pathway dopamine functions in emotion and reward systems. Mesolimbic dopamine mediates pleasure in the brain. It is released during pleasurable situations and stimulates one to seek out the pleasurable activity or occupation. This means food, sex, and several drugs of abuse are also stimulants of dopamine release in the brain, particularly in areas such as the nucleus accumbens and prefrontal cortex. In addition dopamine plays major role in addictions in this pathway. All known drugs of abuse activate the mesolimbic pathway, and plastic changes in this pathway are thought to underlie drug addiction. Antipsychotic drugs that decrease positive symptoms of schizophrenia by blocking dopamine receptors in the mesolimbic pathway [10,12,13].

The Mesocortical Pathway, In which the dopaminergic fibers also arise from the A10 region (the ventral tegmental area) and project to the frontal cortex and septohippocampal regions. Mesocortical dopamine mediates cognitive and emotional behaviour. Levels of dopamine in the brain, especially the prefrontal cortex, help in improved working memory and attentions. However, this is a delicate balance and as levels increase or decrease to abnormal levels, memory suffers. Antipsychotic drugs worsen negative symptoms of schizophrenia by blocking dopamine receptors in the mesocortical pathway [10,12,13].

The Tuberoinfundibular Pathway which originates in the arcuate nucleus of the hypothalamus (arcuate and paraventricular nuclei) and projects to pituitary gland (the median eminence). Dopamine in this pathway inhibit prolactin release. Antipsychotic drugs that block dopamine receptors in the pituitary may thus disinhibit prolactin release and cause galactorrhea. Dopamine is the main neuroendocrine inhibitor of the secretion of prolactin from the anterior pituitary gland. Dopamine produced by neurons in the arcuate nucleus of the hypothalamus is released in the hypothalamo-hypophysial blood vessels of the median eminence, which supply the pituitary gland. This acts on the lactotrope cells that produce prolactin. These cells can produce prolactin in absence of dopamine. Dopamine is occasionally called prolactin-inhibiting factor (PIF), prolactin-inhibiting hormone (PIH), or prolactostatin [14] (Table 2).

Dopamine Synthesis

Dopamine is synthesized from the amino acid tyrosine, which is taken up into the brain via an active transport mechanism. Tyrosine is produced in the liver from phenylalanine through the action of phenylalanine hydroxylase. Tyrosine is then transported to dopamine containing neurons where a series of reactions convert it to dopamine [15,16]. Within catecholaminergic neurons, tyrosine hydroxylase catalyzes the addition of a hydroxyl group to the meta position of tyrosine, yielding L-dopa. This rate-limiting step in catecholamine synthesis is subject to inhibition by high levels of catecholamines (end-product inhibition). Because tyrosine hydroxylase is normally saturated with substrate, manipulation of tyrosine levels does not readily impact the rate of catecholamine synthesis. Once formed, L-dopa is rapidly converted to dopamine by dopa decarboxylase, which is located in the cytoplasm. It is now recognized that this enzyme acts not only on L-dopa but also on all naturally occurring aromatic L-amino acids, including tryptophan, and thus it is more properly termed aromatic amino acid decarboxylase [15,16].

Receptors	Locations	Functions
D1	Found in high concentration in mesolimbic, nigrostriatal and mesocortical areas, such as substantia nigra, olfactory bulb, nucleus accumbens, caudate, putamen, striatum, Expressed in low level in cerebellum, hippocampus, thalamus, hypothalamus, kidney	Voluntary movements, regulate growth and development, regulations of feeding, affect, attentions, reward, sleep, impulse control, reproductive behaviors, working memory, learning, control of rennin in kidney
D2	Expressed in high levels in as substantia nigra, olfactory bulb, caudate, putamen, ventral tegmental area(VTA), nucleus accumbens Found in low level in hypothalamus, septum, kidney, cortex, heart, blood vessels, adrenal glands, gastrointestinal tract, sympathetic ganglia	Involved in working memory, reward-motivation functions regulate blood pressure, renal functions, gastrointestinal motility, vasodilatations, regulate locomotion-presynaptic receptors inhibit locomotion and post synaptic receptors activate locomotion
D3	Expressed only in CNS and it is not found outside the CNS. Found in olfactory bulb, nucleus accumbens	Involved in endocrine function cognitions, emotions, regulations of locomotor functions and modulates endocrine functions
D4	Substantia nigra, hippocampus, amygdala, thalamus, hypothalamus, kidney, frontal cortex, heart, blood vessels, adrenal glands, gastrointestinal tract, sympathetic ganglia, globus palidum, Lowest receptor found in CNS than all dopamine receptors	Regulations of renal functions, gastrointestinal motility, vasodilatations, blood pressure, modulations of cognitive functions
D5	Substantia nigra, hypothalamus, hippocampus, dental gyrus, kidney, heart, blood vessels, adrenal glands, gastrointestinal tract, sympathetic ganglia	Involved in pain process, affective functions, endocrine functions of dopamine

Table 1: Summary of dopamine receptors, locations and functions.

Pathway	Function
Nigrostriatal	Movement and sensory stimuli
Mesolimbic	Pleasure and reward seeking behaviors, addiction, emotion, perception
Mesocortical	Cognition, memory, attention, emotional behavior, and learning
Tuberoinfundibular	Control of the hypothalamic pituitary endocrine system, inhibition of prolactin secretions

Table 2: Summary of dopamine pathways and major functions.

Dopamine and Mental Disorders

Due to extensive localization of dopamine receptor to brain areas and its role in wide range of functions, dopaminergic dysfunction has been implicated in the pathophysiology of schizophrenia, mood disorders, obsessive compulsive disorder (OCD), autism spectrum disorder, attention deficit-hyperactivity disorder (ADHD), tourette's syndrome, substance dependency, Parkinson's disease and other disorders.

The role of dopamine in schizophrenia

Dopamine is among the common neurotransmitters involved in pathogenesis of schizophrenia, largely based on patients' responses to psychoactive agents [17-20]. The role of dopamine in schizophrenia is based on the dopamine Hypothesis which evolved from two observations. First, drug group which blocks dopamine function, known as the phenothiazines, could reduce psychotic symptoms. Second, amphetamines, which increase dopamine release, can induce a paranoid psychosis and exacerbate schizophrenia and that disulfiram inhibits dopamine hydroxylase and exacerbates schizophrenia [17-19].

The role of dopamine in mood disorders

The findings on dopamine in mood disorders suggest that decreased dopamine activity is involved in depression, while increased dopamine function contributes to mania [21]. The role of dopamine in mood disorders is based on evidence that drugs that reduce dopamine concentrations for example, reserpine and diseases that reduce dopamine concentrations (e.g., Parkinson's disease) are associated with depressive symptoms. In contrast, drugs that increase dopamine concentrations, such as tyrosine, amphetamine, and bupropion reduce the symptoms of depression. Recent theories about dopamine and depression are that the mesolimbic dopamine pathway may be dysfunctional in depression and that the dopamine D₁ receptor may be hypoactive in depression [21-25].

The role of dopamine in addictions

Most addictive drugs share the common property of increasing

dopamine release in the striatum. The dopamine input to the striatum is provided by a very dense network of axon terminals arising from cell bodies in the midbrain-substantia nigra pars compacta and ventral tegmental area. The increased locomotor activity and stereotypy caused by psychostimulants seem especially to involve dopamine release in ventral and dorsal parts of striatum, respectively. The ventral striatum includes the "core" and "shell" of the nucleus accumbens, blockade of dopamine neurotransmission in this region attenuates most rewarding effects of addictive drugs, such as conditioned place preference. The dopaminergic projection to ventral striatum has therefore been intensely investigated for its potential involvement in addictions[26-28].

The role of dopamine in attention-deficit hyperactivity disorder (ADHD)

Dopamine is among the common neurotransmitters involved in pathogenesis of Attention-Deficit Hyperactivity Disorder (ADHD). Defects in dopamine metabolism have long been implicated in the etiology of ADHD. The impulse and behavior problems found in Attention-Deficit Hyperactivity Disorder (ADHD) appear related to low levels of Dopamine in the brain. Stimulants increase catecholamine concentrations by promoting their release and blocking their uptake. Stimulants has been helpful in treating hyperactivity. Other drugs that have reduced hyperactivity include tricyclic drugs and monoamine oxidase inhibitors (MAOIs), which indicate role of dopamine in Attention-Deficit Hyperactivity Disorder (ADHD) [29,30].

References

- Seeman P (2009) Chapter 1: Historical overview: Introduction to the dopamine receptors. The Dopamine Receptors. Springer.
- Romanelli RJ, Williams JT, Neve KA (2009) Chapter 6: Dopamine receptor signalling: intracellular pathways to behavior. The Dopamine Receptors. Springer.
- Sadock BJ, Sadock VA, Ruiz P (2009) Kaplan and Sadock's Comprehensive Textbook of Psychiatry. (9thedn) Lippincott Williams & Wilkins, Philadelphia.
- Stahl, SM (2008) Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (3rdedn) Cambridge University Press, New York.
- Grandy DK, Miller GM, Li JX (2016) TAARgeting Addiction" - The Alamo Bears

- Witness to Another Revolution: An Overview of the Plenary Symposium of the 2015 Behavior, Biology and Chemistry Conference". *Drug Alcohol Depend*. 159: 9-16.
6. Rang HP (2003) *Pharmacology*. Edinburgh: Churchill Livingstone. pp. 474 for noradrenaline system, page 476 for dopamine system, page 480 for serotonin system and page 483 for cholinergic system.
 7. Malenka RC, Nestler EJ, Hyman SE (2009) Chapter 6: Widely Projecting Systems: Monoamines, Acetylcholine, and Orexin". In: Sydor A, Brown RY (eds.) *Molecular Neuropharmacology: A Foundation for Clinical Neuroscience*. (2ndedn) New York.
 8. Nestler EJ (2014) *Brain Reward Pathways*. Icahn School of Medicine at Mount Sinai. Nestler Lab. The dorsal raphe is the primary site of serotonergic neurons in the brain, which, like noradrenergic neurons, pervasively modulate brain function to regulate the state of activation and mood of the organism.
 9. Schacter G, Weger (2009) *Psychology*. United States of America.
 10. Malenka RC, Nestler EJ, Hyman SE (2009) Chapter 6: Widely Projecting Systems: Monoamines, Acetylcholine, and Orexin". In: Sydor A, Brown RY. *Molecular Neuropharmacology: A Foundation for Clinical Neuroscience* (2ndedn) McGraw-Hill Medical, New York.
 11. Christine CW, Aminoff MJ (2004) Clinical differentiation of parkinsonian syndromes: prognostic and therapeutic relevance. *The American Journal of Medicine* 117: 412-419.
 12. Björklund A, Dunnett SB (2007) Dopamine neuron systems in the brain: an update. *Trends in Neurosciences* 30: 194-202.
 13. Paulus W, Schomburg ED (2006) Dopamine and the spinal cord in restless legs syndrome: does spinal cord physiology reveal a basis for augmentation. *Sleep Medicine Reviews* 10: 185-196.
 14. Ben-Jonathan N, Hnasko R (2001) Dopamine as a prolactin (PRL) inhibitor. *Endocrine Reviews* 22: 724-763.
 15. Musacchio JM (2013) Chapter 1: Enzymes involved in the biosynthesis and degradation of catecholamines. *Biochemistry of Biogenic Amines*.
 16. The National Collaborating Centre for Chronic Conditions, ed. (2006) *Symptomatic pharmacological therapy in Parkinson's disease*. Parkinson's Disease. London: Royal College of Physicians.
 17. Sadock B J, Sadock VA, Ruiz P (2009) *Kaplan and Sadock's Comprehensive Textbook of Psychiatry*. (9thedn) Lippincott Williams & Wilkins, Philadelphia.
 18. Laruelle M, Abi-Dargham A, van Dyck CH (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. *Proc Natl Acad Sci USA* 93: 9235-9240.
 19. Jones HM, Pilowsky LS (2002) Dopamine and antipsychotic drug action revisited. *Br J Psychiatry* 181: 271-275.
 20. Martin S (2002) *An Atlas of Schizophrenia*. DC: Taylor & Francis, Washington.
 21. Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. *Am J Psychiatry* 122: 509-522.
 22. Niklasson F, Ågren H (1984) Brain energy metabolism and blood-brain barrier permeability in depressive patients: analyses of creatine, creatinine, urate, and albumin in CSF and blood. *Biol Psychiatry* 19:1183- 1206.
 23. Schildkraut JJ, Orsulak PJ, Schatzberg AF, Gudeman JE, Cole JO, et al. (1978) Toward a biochemical classification of depressive disorders. I. Differences in urinary excretion of MHPG and other catecholamine metabolites in clinically defined subtypes of depressions. *Arch Gen Psychiatry* 35: 1427- 1433.
 24. Sweeney DR, Maas JW (1978) Specificity of depressive illness. *Ann Rev Med* 29: 219-229.
 25. Schatzberg AF, Samson JA, Bloomingdale KL, Orsulak PJ, Gerson BK, et al. (1989) Toward a biochemical classification of depressive disorders, urinary catecholamines, their metabolites, and D-type scores in subgroups of depressive disorders. *Arch Gen Psychiatry* 46: 260- 268.
 26. Malenka RC, Nestler EJ, Hyman SE (2009) *Molecular Neuropharmacology: A Foundation for Clinical Neuroscience*. (2ndedn), McGraw-Hill Medical, New York.
 27. Berridge KC, Robinson TE, Aldridge JW (2009) Dissecting components of reward: 'liking', 'wanting', and learning. *Current Opinion in Pharmacology* 9: 65-73.
 28. Wise RA (1996) Addictive drugs and brain stimulation reward. *Annual Review of Neuroscience* 19: 319-340.
 29. Le Moal M, Simon H (1991) Mesocorticolimbic dopaminergic network: functional and regulatory roles. *Physiol Rev* 71: 155-234.
 30. Cook EH, Stein MA, Krasowski MD (1995) Association of attention-deficit disorder and the dopamine transporter gene. *Am J Hum Genet* 56: 993-998.